Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

(2017) Danae A Delivanis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

General and Specific Genetic Polymorphism of Cytokines-Related Gene in AITD

(2017) Chen Xiaoheng et al.   MEDIATORS OF INFLAMMATION

Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study

(2017) Ichiro Yamauchi et al.   THYROID

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

(2017) Hyunju Lee et al.   Cancer Immunology Research

Nivolumab induced myxedema crisis

(2017) Uqba Khan et al.   Journal for ImmunoTherapy of Cancer

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

(2016) Patrizio Caturegli et al.   AMERICAN JOURNAL OF PATHOLOGY

Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review

(2016) M.N Joshi et al.   CLINICAL ENDOCRINOLOGY

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis

(2016) Omar Abdel-Rahman et al.   Future Oncology

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

(2016) Jeroen de Filette et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline

(2016) Maria Fleseriu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

(2016) Stefan R. Bornstein et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Genetic risk factors for type 1 diabetes

(2016) Flemming Pociot et al.   LANCET

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

PD-1 Blockers

(2015) Jedd D. Wolchok   CELL

Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies

(2015) Steven Orlov et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

(2015) Alexander Faje   Pituitary

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

(2014) L. Min et al.   CLINICAL CANCER RESEARCH

Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association

(2014) Jane L. Chiang et al.   DIABETES CARE

Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes

(2014) Asa K. Davis et al.   DIABETES CARE

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

(2014) Mabel Ryder et al.   ENDOCRINE-RELATED CANCER

Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma

(2014) Alexander T. Faje et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations

(2014) Arti Hurria et al.   JOURNAL OF CLINICAL ONCOLOGY

Adrenal insufficiency

(2014) Evangelia Charmandari et al.   LANCET

Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes

(2014) Nora M. Kochupurakkal et al.   PLoS One

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement

(2014) Jacqueline Jonklaas et al.   THYROID

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH

The ineligible patient: how to treat patients not included in clinical studies

(2013) Frances J. Mao et al.   WORLD JOURNAL OF UROLOGY

Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus

(2013) Eiji Kawasaki et al.   Journal of Diabetes Investigation

Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis

(2013) L. Min et al.   Cancer Immunology Research

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

(2010) Le Min et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY